MapLight Therapeutics (MPLT) EPS (Basic) (2024 - 2025)

MapLight Therapeutics recorded quarterly EPS (Basic) of $87.14 in Q4 2025, up 334.37% quarter-over-quarter from -$37.18 in Q3 2025, and up 411.1% year-over-year from $17.05 in Q4 2024.

MapLight Therapeutics' EPS (Basic) history runs 2 years deep, the most recent figure standing at $87.14 for Q4 2025.

  • In Q4 2025, EPS (Basic) rose 411.1% year-over-year to $87.14; the TTM figure through Dec 2025 stood at -$3.13 (changed N/A YoY), while the FY2025 annual figure was -$18.56, up 82.39% from the prior year.
  • EPS (Basic) came in at $87.14 for Q4 2025 at MapLight Therapeutics, up from -$37.18 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $87.14 in Q4 2025 to a low of -$37.18 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EPS (Basic) (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - 3.06
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn 0.00
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - 0.00
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 4.06
7 Evaxion A 64.16 Bn 64.14 Bn - 0.00
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 6.99
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 1.55
10 MapLight Therapeutics 254.43 Mn 254.43 Mn - 87.14

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 87.14
Sep 30, 2025 -37.18
Dec 31, 2024 -28.01
Sep 30, 2024 -25.08